Inclusion Criteria:

          -  Have histologically confirmed Diffuse Large B-Cell Lymphoma that is either:

          -  Refractory after at least one regimen of systemic chemotherapy and/or targeted
             therapy, or

          -  In first or later relapse if have received at least 2 systemic regimens since time of
             diagnosis, or

          -  Relapsed post-autologous or allogeneic HSCT with adequate organ function after
             proximity to transplantation time exclusions as specified in Exclusion Criteria 208
             and 209

          -  Have measureable disease

          -  Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2

          -  Life expectancy of ≥ 12 weeks in the opinion of the Investigator

          -  Biopsy proven DLBCL (biopsy proven at least at primary diagnosis of DLBCL)

        Other Inclusion Criteria May Apply

        Exclusion Criteria:

          -  Richter's transformation (DLBCL arising in the setting of prior chronic lymphocytic
             leukemia) or Primary Mediastinal B cell Lymphoma (PMBCL)

          -  History or presence of clinically relevant Central Nervous System pathology such as
             epilepsy, paresis, aphasia, stroke, severe brain injury, dementia, Parkinson's
             disease, cerebellar disease, organic brain syndrome, or psychosis.

          -  Has a diagnosis of immunodeficiency or has received systemic steroid therapy (in
             excess of 10 mg daily of prednisone equivalent) or any other form of immunosuppressive
             therapy within 7 days prior to the first dose of protocol specified therapy.

          -  Has undergone prior allogeneic HSCT:

          -  within the last 5 years OR

          -  greater than 5 years ago but has active graft versus host disease (GvHD) requiring
             systemic treatment.

          -  Has received autologous HSCT within 6 weeks prior to start of treatment.

        Other Exclusion Criteria May Apply.